Literature DB >> 24189063

CD154 is released from T-cells by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17 in a CD40 protein-dependent manner.

Daniel Yacoub1, Nadir Benslimane, Loubna Al-Zoobi, Ghada Hassan, Amal Nadiri, Walid Mourad.   

Abstract

CD154 (CD40 ligand) is a type II transmembrane protein that belongs to the tumor necrosis factor superfamily. The soluble form of CD154 (sCD154), which results from the shedding of membrane-bound CD154, plays a key role in the production of proinflammatory cytokines and has been linked to various autoimmune and vascular disorders. Therefore, elucidating the mechanisms by which CD154 is released from the cell surface following its interaction with its various receptors is of primordial importance. Using co-culture experiments, we show that CD154 is shed predominantly upon its engagement with CD40. Indeed, only CD40 (both membrane-bound and soluble) and not α5β1 or αMβ2 is involved in the cleavage and release of CD154 from Jurkat E6.1 T-cells. Interestingly, CD154 is cleaved independently of the formation of cell surface CD40 homodimers and independently of its association into lipid rafts. In contrast, we found that the protein kinase C (PKC) signaling family and the matrix metalloproteinases ADAM10 and ADAM17 are intimately involved in this process. In conclusion, our data indicate that CD154 is released from T-cells by ADAM10 and ADAM17 upon CD40 ligation. These findings add significant insights into the mechanisms by which CD154 is down-regulated and may lead to the generation of novel therapeutic targets for the treatment of CD154-associated disorders.

Entities:  

Keywords:  CD154; CD40; Cell Signaling; Inflammation; Integrins; Molecular Biology; Receptors; T-cells

Mesh:

Substances:

Year:  2013        PMID: 24189063      PMCID: PMC3861656          DOI: 10.1074/jbc.M113.506220

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Functional interaction of CD154 protein with α5β1 integrin is totally independent from its binding to αIIbβ3 integrin and CD40 molecules.

Authors:  Youssef El Fakhry; Haydar Alturaihi; Daniel Yacoub; Lihui Liu; Wenyan Guo; Claire Leveillé; Daniel Jung; Lara Bou Khzam; Yahye Merhi; John A Wilkins; Hongmin Li; Walid Mourad
Journal:  J Biol Chem       Date:  2012-03-29       Impact factor: 5.157

2.  Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation.

Authors:  Hyun-Jung An; Young Jin Kim; Dong Hyun Song; Beom Suk Park; Ho Min Kim; Ju Dong Lee; Sang-Gi Paik; Jie-Oh Lee; Hayyoung Lee
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

3.  Different signaling pathways stimulate a disintegrin and metalloprotease-17 (ADAM17) in neutrophils during apoptosis and activation.

Authors:  Yue Wang; John D Robertson; Bruce Walcheck
Journal:  J Biol Chem       Date:  2011-09-23       Impact factor: 5.157

4.  Cleavage of neuregulin-1 by BACE1 or ADAM10 protein produces differential effects on myelination.

Authors:  Xiaoyang Luo; Marguerite Prior; Wanxia He; Xiangyou Hu; Xiaoying Tang; Weizhen Shen; Satya Yadav; Sumiko Kiryu-Seo; Robert Miller; Bruce D Trapp; Riqiang Yan
Journal:  J Biol Chem       Date:  2011-05-16       Impact factor: 5.157

5.  ERK1-independent α-secretase cut of β-amyloid precursor protein via M1 muscarinic receptors and PKCα/ε.

Authors:  Moustapha Cisse; Ursula Braun; Michael Leitges; Abraham Fisher; Gilles Pages; Frédéric Checler; Bruno Vincent
Journal:  Mol Cell Neurosci       Date:  2011-05-04       Impact factor: 4.314

6.  Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cδ, and p38 mitogen-activated protein kinase (MAPK).

Authors:  Edward Thorp; Tomas Vaisar; Manikandan Subramanian; Lauren Mautner; Carl Blobel; Ira Tabas
Journal:  J Biol Chem       Date:  2011-08-02       Impact factor: 5.157

7.  CD40 ligand shedding is regulated by interaction between matrix metalloproteinase-2 and platelet integrin alpha(IIb)beta(3).

Authors:  W-S Choi; O-H Jeon; D-S Kim
Journal:  J Thromb Haemost       Date:  2010-03-03       Impact factor: 5.824

8.  Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice.

Authors:  Dennis Wolf; Jan-David Hohmann; Ansgar Wiedemann; Kamila Bledzka; Hermann Blankenbach; Timoteo Marchini; Katharina Gutte; Katharina Zeschky; Nicole Bassler; Natalie Hoppe; Alexandra Ortiz Rodriguez; Nadine Herr; Ingo Hilgendorf; Peter Stachon; Florian Willecke; Daniel Duerschmied; Constantin von zur Muhlen; Dmitry A Soloviev; Li Zhang; Christoph Bode; Edward F Plow; Peter Libby; Karlheinz Peter; Andreas Zirlik
Journal:  Circ Res       Date:  2011-10-13       Impact factor: 17.367

9.  Critical role of lipid rafts in CD154-mediated T cell signaling.

Authors:  Youssef El Fakhry; Haydar Alturaihi; Djibril Diallo; Yehye Merhi; Walid Mourad
Journal:  Eur J Immunol       Date:  2010-03       Impact factor: 5.532

10.  Requirement of transmembrane domain for CD154 association to lipid rafts and subsequent biological events.

Authors:  Nadir Benslimane; Ghada S Hassan; Daniel Yacoub; Walid Mourad
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

View more
  24 in total

Review 1.  Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.

Authors:  Miles A Miller; Ryan J Sullivan; Douglas A Lauffenburger
Journal:  Clin Cancer Res       Date:  2016-11-28       Impact factor: 12.531

Review 2.  Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats.

Authors:  O Guttman; B M Baranovski; R Schuster; Z Kaner; G S Freixo-Lima; N Bahar; N Kalay; M I Mizrahi; I Brami; D E Ochayon; E C Lewis
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

3.  Assessment of CD40 and CD40L expression in rheumatoid arthritis patients, association with clinical features and DAS28.

Authors:  Ilce Valeria Román-Fernández; Mariel García-Chagollán; Sergio Cerpa-Cruz; Luis Felipe Jave-Suárez; Claudia Azucena Palafox-Sánchez; Samuel García-Arellano; Gabriela Athziri Sánchez-Zuno; José Francisco Muñoz-Valle
Journal:  Clin Exp Med       Date:  2019-07-16       Impact factor: 3.984

4.  Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression.

Authors:  Kiera L Clayton; Matthew B Douglas-Vail; A K M Nur-ur Rahman; Karyn E Medcalf; Irene Y Xie; Glen M Chew; Ravi Tandon; Marion C Lanteri; Philip J Norris; Steven G Deeks; Lishomwa C Ndhlovu; Mario A Ostrowski
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

5.  T-cell trans-synaptic vesicles are distinct and carry greater effector content than constitutive extracellular vesicles.

Authors:  Pablo F Céspedes; Ashwin Jainarayanan; Lola Fernández-Messina; Salvatore Valvo; David G Saliba; Elke Kurz; Audun Kvalvaag; Lina Chen; Charity Ganskow; Huw Colin-York; Marco Fritzsche; Yanchun Peng; Tao Dong; Errin Johnson; Jesús A Siller-Farfán; Omer Dushek; Erdinc Sezgin; Ben Peacock; Alice Law; Dimitri Aubert; Simon Engledow; Moustafa Attar; Svenja Hester; Roman Fischer; Francisco Sánchez-Madrid; Michael L Dustin
Journal:  Nat Commun       Date:  2022-06-16       Impact factor: 17.694

Review 6.  CD40-CD40L in Neurological Disease.

Authors:  Heather D Ots; Jovanna A Tracz; Katherine E Vinokuroff; Alberto E Musto
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

7.  CD40L is transferred to antigen-presenting B cells during delivery of T-cell help.

Authors:  Jennifer L Gardell; David C Parker
Journal:  Eur J Immunol       Date:  2016-11-28       Impact factor: 5.532

8.  Unique Sjögren's syndrome patient subsets defined by molecular features.

Authors:  Judith A James; Joel M Guthridge; Hua Chen; Rufei Lu; Rebecka L Bourn; Krista Bean; Melissa E Munroe; Miles Smith; Eliza Chakravarty; Alan N Baer; Ghaith Noaiseh; Ann Parke; Karen Boyle; Lynette Keyes-Elstein; Andreea Coca; Tammy Utset; Mark C Genovese; Virginia Pascual; Paul J Utz; V Michael Holers; Kevin D Deane; Kathy L Sivils; Teresa Aberle; Daniel J Wallace; James McNamara; Nathalie Franchimont; E William St Clair
Journal:  Rheumatology (Oxford)       Date:  2020-04-01       Impact factor: 7.580

Review 9.  Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?

Authors:  Gustavo Ortiz; Juan P Salica; Eduardo H Chuluyan; Juan E Gallo
Journal:  Biol Res       Date:  2014-11-18       Impact factor: 5.612

Review 10.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.